1

발표평가 대상과제

RFP(지원분야)

발표평가 대상과제-과제번호

(1내역)

신약 기반 확충 연구

유효물질단계

  RS-2023-00258124, RS-2023-00258141, 

  RS-2023-00258166, RS-2023-00258189, 

  RS-2023-00258193, RS-2023-00258659,

  RS-2023-00258665, RS-2023-00258675,

  RS-2023-00258678, RS-2023-00258784, 

  RS-2023-00258840, RS-2023-00258895,

  RS-2023-00259000, RS-2023-00259003, 

  RS-2023-00259057, RS-2023-00259137, 

  RS-2023-00259173, RS-2023-00259174,

  RS-2023-00259272, RS-2023-00259453, 

  RS-2023-00259518

선도물질단계

  RS-2023-00258164, RS-2023-00258235, 

  RS-2023-00258399, RS-2023-00258422, 

  RS-2023-00258722, RS-2023-00258730,

  RS-2023-00258812, RS-2023-00258848, 

  RS-2023-00258885, RS-2023-00258901, 

  RS-2023-00258968, RS-2023-00259315,

  RS-2023-00259507

(2내역)

신약 R&D 생태계 구축 연구

후보물질단계

  RS-2023-00258136, RS-2023-00258156, 

  RS-2023-00258167, RS-2023-00258484, 

  RS-2023-00258490, RS-2023-00258594,

  RS-2023-00258629, RS-2023-00258727, 

  RS-2023-00258762, RS-2023-00258774, 

  RS-2023-00258859, RS-2023-00258926, 

  RS-2023-00259161, RS-2023-00259271, 

  RS-2023-00259365, RS-2023-00259457, 

  RS-2023-00259478, RS-2023-00259485

비임상단계

  RS-2023-00258119, RS-2023-00258121, 

  RS-2023-00258142, RS-2023-00258208, 

  RS-2023-00258260, RS-2023-00258278,

  RS-2023-00258510, RS-2023-00258617, 

  RS-2023-00258714, RS-2023-00258738, 

  RS-2023-00259040, RS-2023-00259081, 

  RS-2023-00259138, RS-2023-00259189, 

  RS-2023-00259217, RS-2023-00259275, 

  RS-2023-00259279, RS-2023-00259281, 

  RS-2023-00259306

(3내역)

신약 임상개발

임상단계

(임상1상, 임상2상)

  RS-2023-00258444, RS-2023-00258708, 

  RS-2023-00258721, RS-2023-00258850, 

  RS-2023-00258953, RS-2023-00259008, 

  RS-2023-00259223, RS-2023-00259300

2

발표평가 안내

3

평가 관련 문의처

이메일

연락처

kddf_pm@kddf.org

02-6379-3083

4

참고사항